



شبكة المعلومات الجامعية
التوثيق الإلكتروني والميكروفيلم

بسم الله الرحمن الرحيم



MONA MAGHRABY



شبكة المعلومات الجامعية
التوثيق الإلكتروني والميكروفيلم



شبكة المعلومات الجامعية التوثيق الإلكتروني والميكروفيلم



MONA MAGHRABY



شبكة المعلومات الجامعية
التوثيق الإلكتروني والميكروفيلم

جامعة عين شمس

التوثيق الإلكتروني والميكروفيلم

قسم

نقسم بالله العظيم أن المادة التي تم توثيقها وتسجيلها
علي هذه الأقراص المدمجة قد أعدت دون أية تغيرات



يجب أن

تحفظ هذه الأقراص المدمجة بعيدا عن الغبار



MONA MAGHRABY

**Role of Circulating Myeloid-Derived
Suppressor Cells in Pathogenesis of Immune
Thrombocytopenia in Children
and Adolescents**

A Thesis

Submitted for partial fulfillment of Master degree
in Pediatrics

By

Fatma Ahmed Bayomi

M.B.,B.Ch (2009). Faculty of Medicine, Ain Shams University

Under Supervision of

Prof. Dr. Nevine Gamal Andrawes

Professor of Pediatrics

Faculty of Medicine, Ain Shams University

Prof. Dr. Mohamed Tarif Hamza

Professor of Clinical Pathology

Faculty of Medicine, Ain Shams University

Dr. Heba Gomaa Abd Elraheem

Lecturer of Pediatrics

Faculty of Medicine, Ain Shams University

**Faculty of Medicine
Ain Shams University**

2020

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

قَالَ

سَبِّحْكَ لَا يَلْمُ لَنَا
إِلَّا مَا عَلِمْنَا إِنَّكَ أَنْتَ
الْعَلِيمُ الْعَظِيمُ

صدق الله العظيم

سورة البقرة الآية: ٣٢

Acknowledgments

*First and foremost, I feel always indebted to **Allah**, the Most Beneficent and Merciful, Who gave me the strength to accomplish this work,*

*I would like to forward my sincere appreciation to **Dr. Nevine Gamal Andrawes**; Professor of Pediatrics, Ain Shams University, for giving me the privilege of working under her supervision, also for dedicating much of her precious time, and wide experience that guided this work to succeed.*

*Also, I am deeply indebted to **Dr. Mohamed Tarif Hamza**, Professor of Clinical pathology, Ain Shams University, for his utmost help, kind indispensable guidance, valuable instruction.*

*I would like to express my deep and sincere gratitude and thanks to **Dr. Heba Gomaa Abd El Raheem**, Lecturer of pediatrics, Ain Shams University, for her valuable help and tremendous effort she offered me during preparation of this study and for dedicating much of her precious time.*

I extend my sincere thanks and appreciation to Dr. Mohamed Shoman, for the useful assistance he provided and technical support.

A due thanks to the patients who agreed to participate in this study and helped us to reach our aim and results.

I extend my deep gratitude to my family and my husband for their generous support.

 **Fatma Ahmed Bayomi**

List of Contents

<i>Subject</i>	<i>Page No.</i>
List of Abbreviations	i
List of Tables.....	iii
List of Figures	v
Abstract	vii
Introduction	1
Aim of the Work	4
Review of Literature.....	4
Patients and Methods	58
Results.....	67
Discussion	90
Summary	98
Conclusion	102
Recommendations.....	103
References.....	104
Arabic Summary.....	—

List of Abbreviations

Abbr.	Full-term
ACK	: Ammonium Chloride Potassium
ANA	: Anti-Nuclear Antibodies
APS	: The antiphospholipid syndrome
Arg1	: Arginase 1
ASH	: The American Society of Hematology
BAFF	: B-lymphocyte Activating Factor
BM	: Bone marrow
BMMCs	: Bone Marrow Mononuclear Cells
BSA	: Bovine Serum Albumin
Cag A	: Cytotoxin - associated gene A
CIN	: Chronic Idiopathic Neutropenia
CMPs	: Common Myeloid Progenitors.
CMV	: Cytomegalovirus
COVID 19	: Corona Virus Disease
COX1	: Cyclo-Oxygenase 1
CRP	: C- Reactive Protein
CSFs	: Colony-Stimulating Factors
DC	: Dendritic Cell
DXM	: Dexamethasone
EBV	: Epstein Barr Virus
EDTA	: Ethylene Diamine Tetra Acetic acid
ESR	: Erythrocyte Sedimentation Rate
eTPO	: Endogenous Thrombopoietin
FcγR	: Fc Gamma Receptor
fl	: Femtoliters

g/dl	: Grams per decilitre
GCs	: Glucocorticoids
GPs	: Platelet Membrane Glycoproteins
H Pylori	: Helicobacter pylori
HCV	: Hepatitis C Virus
HD-DXM	: High Dose Dexamethasone
HIV	: Human Immunodeficiency Virus
HLA	: Human leucocyte antigen
HPA	: Human platelet antigen
HRQoL	: Health Related Quality of Life
HSCT	: Hematopoietic Stem Cell Transplantation
ICIs	: anti-Checkpoint Inhibitors
IDO	: Indoleamine 2,3 Di-Oxygenase
IgG	: Immunoglobulin G
IgM	: Immunoglobulin M
IL1-RA	: Interleukin 1 Receptor Antagonist
IL10	: Interleukin 10
ITP	: Immune thrombocytopenia
IVIG	: Intravenous Immunoglobulins
IWG	: International Working Group
MCV	: Mean Corpuscular Volume
MDSCs	: Myeloid-Derived Suppressor Cells
MHC	: Major Histocompatibility Complex
MICA	: MHC I chain related gene A
Mi RNA	: Micro RNA
ML	: Milliliters
MO-MDSCs	: Monocytic Myeloid-Derived Suppressor Cells
ms	: Months

MΦ	: Macrophage
NOS	: Nitric Oxide Synthase 2
PBMCs	: Peripheral Blood Mononuclear Cells
PBS	: Phosphate Buffered Saline
PD-L1	: Programmed Death-Ligand 1
PTPN22	: Protein Tyrosine Phosphate Non receptor type22
RA	: Rheumatoid Arthritis
RhIG	: Rh ₀ D Immune Globulin
ROS	: Reactive Oxygen Species
SLE	: Systemic Lupus Erythematosus
TCR	: T-cell Receptor
T1D	: Type 1 Diabetes mellitus
Th1	: T helper 1
Th2	: T helper 2
TGF-β	: Transforming Growth Factor - beta
TLC	: Total Leukocytic Count
TNF-α	: Tumor Necrosis Factor - alpha
TPO-R	: Thrombopoietin Receptor
TPO-RA	: Thrombopoietin Receptor Agonist
Tregs	: Regulatory T cells
USA	: United States of America

List of Tables

Table No.	Title	Page No.
Table (1):	Polymorphisms associated with ITP.	12
Table (2):	The role of infections in ITP pathogenesis.	14
Table (3):	Summary of ASH 2019 recommendations.	22
Table (4):	Recommendations from 2011 ASH guideline for ITP that are not addressed in the 2019 ASH guideline on ITP.	25
Table (5):	Standard first-line therapy for ITP	31
Table (6):	Demographic data of Patients groups.....	67
Table (7):	ITP activity among patients' groups	69
Table (8):	Comparison between patients and controls regarding some demographic data	70
Table (9):	CRP, ALT and S. Creatinine among studied patients with ITP	71
Table (10):	Viral serology among studied patients with ITP.....	71
Table (11):	Comparison between patients with ITP and control as regards hematological data.....	72
Table (12):	Comparison between Patients and controls regarding MDSCs level.	74
Table (13):	Comparison between different types of ITP regarding demographic data	75

Table (14):	Comparison between different types of ITP regarding modality of treatment	77
Table (15):	Comparison between different types of ITP regarding MDSCs	78
Table (16):	Comparison between acute ITP and control regarding demographic data and laboratory data.....	79
Table (17):	Comparison between persistent ITP and control regarding demographic data and laboratory data	82
Table (18):	Comparison between chronic ITP and control regarding demographic data and laboratory data	82
Table (19):	Comparison between patients with active disease status and in remission regarding hematological parameters.....	86
Table (20)	Correlation between level of MDSC and some parameters	89

List of Figures

Figure No.	Title	Page No.
Figure (1):	Immune thrombocytopenia pathogenesis.....	15
Figure (2):	The immune thrombocytopenic purpura bleeding score assessment.....	29
Figure (3):	Therapeutic mechanisms of current ITP treatments.....	38
Figure (4):	Tolerance to self-antigens.....	41
Figure (5):	Role of Tregs in ITP	46
Figure (6):	Myeloid cell differentiation under normal and tumor-induced conditions.....	48
Figure (7):	Role of MDSCs	51
Figure (8):	Schematic of possible pathways of MDSC differentiation in cancer	55
Figure (9):	Schematic role of MDSCs in autoimmune diseases	56
Figure (10):	Principle of the test	64
Figure (11):	Representative flow cytometry showing labelling and gating strategies for myeloid-derived suppressor cells (MDSC). MDSCs were defined as CD33+/CD11b+/HLA-DR- cells.....	65
Figure (12):	Classification of ITP in patients group according to onset of presentation.....	68

Figure (13):	Different types of ITP according to activity	69
Figure (14):	Comparison between Patients and Controls regarding Sex	70
Figure (15):	Comparison between Patients and Controls regarding PLT count	73
Figure (16):	Comparison between Patients and Controls regarding MDSCs level	74
Figure (17):	Comparison between different types of ITP regarding disease interval	76
Figure (18):	Comparison between different types of ITP regarding age	76
Figure (19):	Comparison between Acute and Controls regarding PLT level	80
Figure (20):	Comparison between Acute and Controls regarding MDSCs level	80
Figure (21):	Comparison between Chronic ITP and Controls regarding PLT level	84
Figure (22):	Comparison between Chronic and Controls regarding MDSCs level	84
Figure (23):	Sensitivity & Specificity of MDSCs level	88

Abstract

Background: Regulatory T cells have an immunosuppressive function on T cell activation. They are involved in pathophysiology and treatment of immune thrombocytopenia (ITP). Circulating myeloid-derived suppressor cells (cMDSCs) are involved in immune dysregulation in ITP. **Study objective** was to determine the mean level of MDSCs in acute, persistent and chronic ITP, and its impact on treatment modalities and prognosis. **Patients and Methods:** Forty-one patients with ITP were recruited from Pediatric hematology clinic, Ain Shams University. They were classified into acute, persistent and chronic. they were compared to 20 age and gender matched as healthy controls. All patients were subjected to history taking with emphasis on age of presentation, disease duration and treatment modalities, thorough clinical examination. Mean values of CRP, ALT, S. Creatinine were collected from patients' files. All study participants have performed CBC (Coulter), MDSCs by flow cytometry. Secondary thrombocytopenia was excluded. **Results:** Acute ITP was detected in 29%, 24% had persistent and 46% had chronic ITP. Their age ranged from 1- 16 years at study entry, 51.2% were male. Active disease was found in 58.5% while 41.4% in remission. No treatment was offered to 53% while 24% of patients were on steroids. MDSCs decreased significantly in ITP patients Vs control group ($P < 0.001$) while didn't show significant difference among patients' group regarding MDSCs level as P value =0.325 or with different treatment modalities. **Conclusion:** Reduced numbers of MDSCs play a role in pathogenesis of ITP. Yet, MDSCs didn't differ according to disease duration or treatment modalities.

Keywords: Immune Thrombocytopenia, Pediatric, T lymphocyte, MDSC
